EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Prescriptions of CYP3A4‐ and P‐gp inducers for patients on direct oral anticoagulants: Bridging the gap between epidemiology and patient management for optimal thromboembolic event prevention

Stephanie C M Wuyts iD, Joris De Moor iD, Kristin Jochmans iD, Pieter-Jan Cortoos iD, Fenne Vandervorst iD, Stephane Steurbaut iD, Alain G Dupont iD, Pieter Cornu iD

British Journal of Clinical Pharmacology · 2025

DOI: 10.1002/bcp.70007 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift British Journal of Clinical Pharmacology, 2025. Verfasst von Stephanie C M Wuyts und 7 weiteren Autor:innen. Beteiligte Einrichtung: Pharmacy Department, Universitair Ziekenhuis Brussel (UZ Brussel), Brussels, Belgium. Hauptthemen laut MEDLINE: Thromboembolism, Anticoagulants, Cytochrome P-450 CYP3A Inducers. Die Arbeit nennt 109 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Direct oral anticoagulants (DOACs) are frequently used for the treatment and prevention of ischaemic stroke in patients with non‐valvular atrial fibrillation. Compared to vitamin K antagonists, DOACs have significant advantages, although their drug–drug interaction (DDI) profile may complicate drug efficacy and safety. This narrative review addresses the clinical challenges posed by these DDIs and the potential pharmacological alternatives and monitoring strategies available. A PubMed search was conducted (1 January 2000–31 December 2023) including human DDI studies on DOAC use and CYP3A4/P‐gp inducers in adult patients, evaluating patient outcome data and recommendations for DDI management. Twenty‐two studies were included. Case reports ( n = 6) indicated that antiepileptic drugs such as carbamazepine, phenobarbital and phenytoin may be associated with thromboembolic events. The nested case–control studies ( n = 2) and cohort studies ( n = 9) found that co‐administration of DOACs and CYP3A4/P‐gp inducers, particularly carbamazepine and phenytoin, increased the risk of thromboembolic events. Pharmacovigilance database analyses indicated a significant association between DOAC DDIs and increased reported stroke rates. Management recommendations in systematic reviews ( n = 5) highlighted monitoring when DOACs were combined with inducers. Strategies included using alternative drugs with a weaker or preferentially absent inducing profile. Limited evidence suggests that edoxaban may be an acceptable option in case of DOAC and CYP3A4/P‐gp inducer interactions; however, robust clinical data confirming safety are needed. Present literature indicates a higher thromboembolic risk in patients on DOAC treatment combining CYP3A4‐ and/or P‐gp inducers. DOAC management should be tailored to the individual patient through collaboration between expert healthcare professionals.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ThromboembolismAnticoagulantsCytochrome P-450 CYP3A InducersHumansDrug InteractionsCytochrome P-450 CYP3AAdministration, OralAtrial FibrillationAnticonvulsantsFactor Xa InhibitorsPharmacovigilance

Stichwörter der Autor:innen

P‐glycoproteincytochrome P450 3A4 protein, humandirect oral anticoagulantsdrug interactions

Substanzen

AnticoagulantsCytochrome P-450 CYP3ACytochrome P-450 CYP3A InducersCYP3A4 protein, humanAnticonvulsantsFactor Xa Inhibitors

Autor:innen und Institutionen

  • Pharmacy Department, Universitair Ziekenhuis Brussel (UZ Brussel), Brussels, Belgium.
  • Research Centre for Digital Medicine, Vrije Universiteit Brussel (VUB), Brussels, Belgium.
  • Department of Neurology, Universitair Ziekenhuis Brussel (UZ Brussel), Brussels, Belgium.
  • NEUR Research Group, Center for Neurosciences (C4N), Vrije Universiteit Brussel (VUB), Brussels, Belgium.
  • Department of Hematology, Universitair Ziekenhuis Brussel (UZ Brussel), Brussels, Belgium.
  • Vitality Research Group, Vrije Universiteit Brussel (VUB), Brussels, Belgium.

ORCID-Profile: Stephanie C M Wuyts, Joris De Moor, Kristin Jochmans, Pieter-Jan Cortoos, Fenne Vandervorst, Stephane Steurbaut, Alain G Dupont, Pieter Cornu

Zitieren

APA

Wuyts, S. C. M., Moor, J., Jochmans, K., Cortoos, P. J., Vandervorst, F., Steurbaut, S., Dupont, A. G., & Cornu, P. (2025). Prescriptions of CYP3A4‐ and P‐gp inducers for patients on direct oral anticoagulants: Bridging the gap between epidemiology and patient management for optimal thromboembolic event prevention. British Journal of Clinical Pharmacology. https://doi.org/10.1002/bcp.70007

Vancouver

Wuyts SCM, Moor J, Jochmans K, Cortoos PJ, Vandervorst F, Steurbaut S, et al. Prescriptions of CYP3A4‐ and P‐gp inducers for patients on direct oral anticoagulants: Bridging the gap between epidemiology and patient management for optimal thromboembolic event prevention. British Journal of Clinical Pharmacology. 2025. doi:10.1002/bcp.70007

BibTeX
@article{Wuyts2025,
  author = {Wuyts, Stephanie C M and Moor, Joris De and Jochmans, Kristin and Cortoos, Pieter-Jan and Vandervorst, Fenne and Steurbaut, Stephane and Dupont, Alain G and Cornu, Pieter},
  title = {Prescriptions of CYP3A4‐ and P‐gp inducers for patients on direct oral anticoagulants: Bridging the gap between epidemiology and patient management for optimal thromboembolic event prevention},
  journal = {British Journal of Clinical Pharmacology},
  year = {2025},
  doi = {10.1002/bcp.70007}
}
Kostenlos starten →